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Abstract
This study provides a novel view on the interactions between the MS-KIF18A, a kinesin protein, and estrogen receptor alpha
(ERa) which were studied in vivo and in vitro. Additionally, the regulation of MS-KIF18A expression by estrogen was
investigated at the gene and protein levels. An association between recombinant proteins; ERa and MS-KIF18A was
demonstrated in vitro in a pull down assay. Such interactions were proven also for endogenous proteins in MBA-15 cells
were detected prominently in the cytoplasm and are up-regulated by estrogen. Additionally, an association between these
proteins and the transcription factor NF-kB was identified. MS-KIF18A mRNA expression was measured in vivo in relation to
age and estrogen level in mice and rats models. A decrease in MS-KIF18A mRNA level was measured in old and in OVX-
estrogen depleted rats as compared to young animals. The low MS-KIF18A mRNA expression in OVX rats was restored by
estrogen treatment. We studied the regulation of MS-KIF18A transcription by estrogen using the luciferase reporter gene
and chromatin immuno-percipitation (ChIP) assays. The luciferase reporter gene assay demonstrated an increase in MS-
KIF18A promoter activity in response to 10
28 M estrogen and 10
27M ICI-182,780. Complimentary, the ChIP assay quantified
the binding of ERa and pcJun to the MS-KIF18A promoter that was enhanced in cells treated by estrogen and ICI-182,780. In
addition, cells treated by estrogen expressed higher levels of MS-KIF18A mRNA and protein and the protein turnover in
MBA-15 cells was accelerated. Presented data demonstrated that ERa is a defined cargo of MS-KIF18A and added novel
insight on the role of estrogen in regulation of MS-KIF18A expression both in vivo and in vitro.
Citation: Zusev M, Benayahu D (2009) The Regulation of MS-KIF18A Expression and Cross Talk with Estrogen Receptor. PLoS ONE 4(7): e6407. doi:10.1371/
journal.pone.0006407
Editor: Jose Vina, University of Valencia, Spain
Received January 19, 2009; Accepted June 17, 2009; Published July 28, 2009
Copyright:  2009 Zusev, Benayahu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by CellProm project, FP6th of the European Community (NMP4-CT-2004-500039) and internal grant from Tel Aviv University.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dafnab@post.tau.ac.il
Introduction
Kinesins are microtubule-dependent motor proteins, with more
than 45 members expressed in mammalian cells. Kinesins are
classified based on three structural and functional regions: (i) a
motor domain with microtubule binding site and a catalytic
ATPase domain; (ii) central alpha-helical-coiled coil region which
possesses protein-protein interactions and (iii) tail which interacts
with cargo [1]. Different kinesin proteins share high homology of
their motor domain but diverge considerably in the cargo-binding
tail. Structural heterogeneity of kinesins is the basis for their
diverse functions in various cellular processes including transport
of cargoes such as membranous organelles, macromolecular
complexes and mRNA [2–7]. It has been shown that kinesins
play a role in trafficking directed towards the cell periphery, for
example motility from the Golgi to the plasma membrane [8].
MS-KIF18A is a member of Kinesin-8 sub family [9] which was
cloned from the marrow stromal cells and characterized by
bioinformatic and biochemical means [10,11]. Estrogen receptor
alpha (ERa) was identified as a cargo for MS-KIF18A. We also
suggested a role for this kinesin in estrogen signaling pathway [12].
Estrogen has pivotal functions in both female and male physiology
and has been recognized as a regulator of bone remodeling in
maintaining of bone mass and keeping the balance between bone
formation and resorption [13–15]. Estrogen deficiency in vivo is
recognized during post-menopause or following ovariectomy and
associated with an increase of osteoclasto-genesis and decrease in
osteogenesis that lead to bone destruction [16–19]. Estrogen
hormone action affects cell proliferation and differentiation via the
estrogen receptors (ERs). The ERs are expressed in various cells
including osteoblasts [12,20–24], osteocytes [25] osteoclasts [26]
and mammary epithelial cells [27]. Specifically, ERa is identified
in two isoforms: 66 kDa and 46 kDa, the shorter form lacking a
ligand-independent activation function domain 1 (AF-1) [28,29].
Steroid hormone binding to the receptors leads to a rapid
(second – minutes) non-genomic signal transduction or to a
prolonged genomic signaling [30]. The non-genomic pathway is
mediated by activation of Mitogen Activated Protein Kinase
(MAPK) proteins such as p38 and ERK1/2 [31] and increase in
Ca
2+ ion concentration [32,33] or Inositol 1, 4, 5-trisphosphate
(IP3) [34]. Such activation controls various cellular activities
including cell proliferation, response to inflammation mediated via
inhibition of NF-kB activation [35] and anti-apoptotic events [36–
38]. The prolong estrogen action occurs within 30–60 minutes
where the receptor is translocated to the nucleus and leads to
genomic response. The ERa binds directly to estrogen response
elements (EREs) [39] or indirectly via accessory proteins on AP-1
or Sp-1 binding sites [40] on promoters of target genes. The ERa
translocation to the nucleus is a dynamic process regulated by
ATP activity or by ligand-induced conformational changes and
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6407proteasome function. Depletion of ATP retards the intra-nuclear
mobility of un-liganded ERa and causes the receptor redistribu-
tion to the cytoplasm [41]. When cells’ treated with either 17bE2
or tamoxifen prior to ATP depletion the ERa was less mobile,
more prominent in the nucleus and reduced the shuttling to the
cytoplasm [42]. The ERa shuttling as ATP-dependent phenom-
ena implies a role of motor protein in this process; however, thus
far a candidate for such protein was not identified.
In this study, we presented two views on the MS-KIF18A - ERa
cross talk: one aspect investigated the complex formation between
MS-KIF18A and ERa and the second studied the regulation of
MS-KIF18A expression under estrogen paradigm. The nature of
interactions between ERa and MS-KIF18A was demonstrated
using recombinant and endogenous proteins by immunoprecipita-
tion (IP) and western blot (WB) assays. MS-KIF18A mRNA
expression was analyzed in vivo in bone marrow cells or in vitro in a
pre-osteogenic MBA-15 cells and breast carcinoma MCF-7 cells
that are estrogen responsive cells. Estrogen effects on the binding of
ERa and pcJun to MS-KIF18A promoterwasstudied by chromatin
immunoprecipitation (ChIP) and the activation of the promoter was
analyzed by luciferase reporter assay. The regulation of
MS-KIF18A protein expression and turnover was explored by
metabolic labeling and immunological analysis. The present
research provides a novel view on regulation of MS-KIF18A and
its’ association with ERa and significantly contributes to the
profound understanding of estrogen mediated activities.
Results
The association between MS-KIF18A and a putative cargo; ERa
was demonstrated in our laboratory in earlier study [12]. Currently,
we elaborated on the interactions between these proteins using an in
vitro pull down assay which applied recombinant proteins. We used
three recombinant isoforms of MS-KIF18A: full length of
MS-KIF18A (Figure 1A) and truncated forms: 1–635 AA that
includes the motor domain and the coiled-coil region (Figure 1B)
and 635–898 AA that contains the cargo binding domain
(Figure 1C). The protein associationbetween the three MS-KIF18A
constructs and ERa was demonstrated by Co-IP and WB using
three antibodies: a polyclonal anti-MS-KIF18A which identifies an
epitope at the motor domain, a monoclonal anti-MS-KIF18A
which identifies an epitope at the cargo-binding domain and anti-
ERa (Figure 1D–1F). In addition, we previously demonstrated
interactions of endogenous proteins in MBA-15 cells and revealed
an association of MS-KIF18A with both 46 kDa and 66 kDa ERa
isoforms [12]. Herein,we analyzed the 17bE2 effect on this complex
formation in MBA-15 cells. Cells were pre-incubated in steroid-free
serum for 48 h and then challenged with 10
28 M1 7 bE2 for 16 h
followed with IP using either anti-MS-KIF18A or anti-ERa and
analyzed by WB. In the treated cells, we detected a reduction in
ERa appearance and an increase in MS-KIF18A-46 kDa ERa
complex formation (Figure 2).
MS-KIF18A sub-cellular distribution and co-expression with
ERa was analyzed at the cytoplasm (C) and nuclear/membrane
(N/M) compartments. The ERa expression was identified at
higher level in the nucleus, while MS-KIF18A was prominently
localized in the cytoplasm (Figure 3A). IP with anti-MS-KIF18A
and WB analysis with anti-ERa detected the MS-KIF18A-ERa
complex mainly at the cytoplasm (Figure 3B). To elaborate on the
role of MS-KIF18A in ERa signaling pathway we analyzed the
interactions of ERa and MS-KIF18A with NF-kB (p65 and p50
subunits). Cell lysates were immunoprecipitied with antibodies
towards p65 and p50 subunites of NF-kB and follwed with WB
analysis using anti-MS-KIF18A. An association was found
between MS-KIF18A and p50, whereas no interactions with p65
was observed (Figure 4A). However, protein complex was noted
between ERa and both forms of NF-kB (Figure 4B).
The role of estrogen on MS-KIF18A mRNA expression was
analyzed in vivo and in cell culture. MS-KIF18A mRNA measured in
vivo on RNA isolated from bone marrow cells harvested from rats and
mice and correlated the expression levels in relation to animal age
(Figure 5A, 5B). Studying mice, we measured 6-folds higher mRNA
levels in young males then in old animals (p=0.0019, Figure 5A). In
rats, the expression of the mRNA was 4-folds higher in young male
animals than in old ones (p=0.0022, Figure 5B). In young female
OVX-rats the level of mRNA was 3-folds higher compared to old
ones (p=0.0047, Figure 5B). All together, we noted a higher MS-
KIF18A mRNA levels in bone marrow of young animals that was
decreased with age. In addition, we analyzed sham ratsthat expressed
MS-KIF18A mRNA levels 3-folds higher as compared to OVX-rats
(p=0.0084, Figure 5C). When OVX-rats were treated with 17bE2,a
12.5-folds increase in mRNA levels was detected (p=0.0078,
Figure 5C). These results provide the in vivo evidence of estrogen
impact on the regulation of MS-KIF18A expression.
The stimulatory effect of 17bE2 on MS-KIF18A mRNA
expression led us to analyze the transcription regulation using a
reporter gene assay. We analyzed in silico, the 1500 bp upstream to
the TSS of the MS-KIF18A gene. This region was predicted as
putative promoter and mapped for transcription factors (TFs)
binding sites and regulatory elements. Bioinformatics analysis using
MatInspector software enables to identify the promoter region and
the TF binding sites and regulatory elements. Specifically, we
mapped a non-palindrome half-site ERE that binds ER directly and
AP-1 site that binds ER via accessory proteins such the pcJun. We
amplified this genomic region by PCR and cloned into pGLuc
vector upstream to luciferase reporter gene (pGluc-K) (Figure 6A).
The cloned pGluc-K plasmid was co-transfected with b-galactosi-
dase (b-GAL) plasmid in MCF-7 cells that were treated with
10
28 M1 7 bE2 or/and 10
27 M ICI 182,780 for 1 h or 24 h. The
promoter activity was quantified by luciferase activity normalized to
b-GAL (which indicates the transfection efficiency). In 17bE2
treatedcells’we measuredanincrease inluciferase activity: 1.5-folds
after 1 h (p=0.0001) and 1.7-folds after 24 h (p=0.01) as
compared to control cells. Cells treated with ICI-182,780
demonstrated an increase of luciferase activity; 1.6-folds following
1 h (p=0.02) and 1.5-folds after 24 h (p=0.006) as compared to
untreated cells. The combined treatment of 17bE2/ICI-182,780
resulted with a similar increase of luciferase activity after 1 h
(p=0.0012) and increase 2.5-folds after 24 h (p=0.023) of
treatment (Figure 6C). No activity in transfected cells with
pGLuc-basic plasmid was detected (Figure 6B).
ChIP assay was applied to correlate the endogenous regulation
of promoter activity. We used antibodies to ERa and pcJun to
measure their binding to MS-KIF18A promoter in MCF-7 and
MBA-15 cells (Figure 7). In MCF-7 cells treated with 17bE2 for
60 min, we noted 4-folds increase in ERa binding (p=0.0007,
Figure 7A) while no change in the level of pcJun binding
(Figure 7B) was observed. When the MCF-7 cells were treated
with ICI-182,780, binding of ERa was 9-folds higher (p=0.0001,
Figure 7A) and the binding of pcJun was 2-folds higher (Figure 7B)
as compared to untreated cells. Treatment of MBA-15 cells with
17bE2 for 2 h then ChIPed with anti-ERa revealed a 2-folds
increase of ERa binding to the analyzed promoter (p=0.0281,
Figure 7C) as compared to untreated cells.
The consequence of 17bE2 or ICI-182,780 regulation of ERa
and pcJun binding to MS-KIF18A promoter and its’ activation led
us to study the MS-KIF18A mRNA expression level under this
paradigm. The message expression level was quantified by
MSKIF18A Expression and Cargo
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treatment for 1 h measured 2-folds increase (p=0.0014) while
treatment with ICI-182,780 induced 34-folds increase (p=0.014)
of MS-KIF18A mRNA expression (Figure 8A). MBA-15 cells
treatment with 17bE2 resulted with 1.3-folds elevation mRNA
levels after 2 h (p=0.0001) and 1.8- folds after 24 h (p=0.0053) as
compared to untreated control (Figure 8B).
Actinomycin D (ActD) is an inhibitor of RNA synthesis. We
measured the mRNA levels in cells treated by this drug in presence
or absence of 17bE2 and noted a 25-folds increase in mRNA levels
in ActD/E2 treated cells as compared to cells’ treated by ActD
only (p=0.0001, Figure 8C) indicating mRNA stabilization in cells
treated with estrogen.
Additionally, we followed the MS-KIF18A protein in MBA-15
cells treated by 17bE2 for defined periods from 1 h to 20 h. The cell
lysates were separated on SDS-PAGE gel and analyzed by WB with
anti-MS-KIF18A. We noted an increase in MS-KIF18A protein
expression already after 1 h of treatment that was maintained until
20 h (Figure 9A). In addition, MS-KIF18A protein turnover was
analyzed in presence or absence of estrogen applying metabolic
labeling with Met/Cis-S
35 on MBA-15 cells. The cells were
pretreated for 6 h, 24 h or 48 h with 17bE2, radio-labeled for 1 h
and then chased at 4 time points from 1 h to 36 h. At each time
Figure 1. Association between MS-KIF18A and ERa recombinant proteins. Schematic illustration of full length MS-KIF18A (A); truncated MS-
KIF18A construct 1–635 aa (B); truncated MS-KIF18A construct 635–898 aa (C). (D–F) Co-IP experiments of MS-KIF18A constucts with recombinant
ERa and WB with monoclonal anti-MS-KIF18A (1) and anti-ERa (2). Full length MS-KIF18A (D), MS-KIF18A constucts 1–635 aa (E), MS-KIF18A constucts
635–898 (F). Pull down with beads only (1); IP with anti-MS-KIF18A and WB with anti-ERa (2) (G). The results are representative from the set of at least
three independent experiences.
doi:10.1371/journal.pone.0006407.g001
Figure 2. Estrogen-dependent association between MS-KIF18A
and ERa. MBA-15 cell lysates were IPed with anti-ERa or anti-MS-
KIF18A, and analyzed by WB. Results are of representative experiment
of a series repeated five times.
doi:10.1371/journal.pone.0006407.g002
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SDS-PAGE and exposed to developing film (Figure 9B). A 100 kDa
band was identified and confirmed by IP and WB analysis as
MS-KIF18A (Figure 9C). We have shown MS-KIF18A protein
degradation in period of 24 h to 36 h after cells’ labeling. The
estrogen treatment induced an increase of MS-KIF18A synthesis
(1 h chase), accelerated protein turnover (12 h chases) and
shortened its half-life (36 h chase). In addition, other prominent
proteins of 230 kDa and 45 kDa (earlier identified as actin [11])
were Co-IPed by anti-MS-KIF18A (Figure 9B).
In summary, we demonstrated the association between MS-
KIF18A and ERarecombinant and endogenous proteins analyzed in
MBA-15 cells. These proteins’ association was regulated by 17bE2
and the complex appeared more prominent in cytoplasm. At the
molecular level, we demonstrated estrogen dependent activation of
MS-KIF18A promoter measured by luciferase assay and an
estrogenic increase in ERa and pcJun binding to the promoter.
The regulation of MS-KIF18A mRNA and protein expression by
estrogen was demonstrated in vivo in mice and rats as well as in cell
systems.
Discussion
MS-KIF18A is a member of kinesin family, which functions as
motor protein that binds to microtubule and uses the energy derived
from ATP hydrolysis to move along the cytoskeleton. Previous studies
analyzedtheMS-KIF18Ausingbioinformaticsandbiochemicaltools
suggested the estrogen receptor alpha (ERa) as a putative cargo [10–
12]. The present study elaborated on two aspects; one highlighted on
the interactions between MS-KIF18A and ERa and the second
studied the expression of MS-KIF18A under the paradigm of
estrogen which applied in vivo and in vitro models.
The complex formation between motor proteins and their cargo
comes from the motifs that play a role in protein-protein
interactions. Bioinformatics analysis of MS-KIF18A protein
sequence revealed several motifs of interaction with nuclear
receptors (NR-boxes and WXXWW-like motifs) and a region
homologous to ERa in the coiled coil and the cargo-binding
domains of the kinesin. Co-transfection of MS-KIF18A and ERa
in COS-7 null cells and also Co-IP of endogenous proteins in
MBA-15 cells demonstrated such association [10,12]. Here, we
elaborated on the nature of these proteins interactions in in vitro
assay using three constructs of recombinant MS-KIF18A and
ERa. We have shown that full length MS-KIF18A or its truncated
forms bind the ERa. Thus, we propose a putative function for the
NR motifs localized at the coiled-coil region and cargo-binding
domain of the MS-KIF18A, in mediating the proteins interactions.
Estrogen is recognized to activate numerous of transcriptional
events in many cell types. Estrogen receptor localization was noted
at various cell compartments that are down regulated in cells
treated by 17bE2 [43,44]. ERa shuttles between different cellular
compartments including cell membrane, cytoplasm and nucleus
[12,30,43]. A small portion of ERa is localized at the caveolar
fractions of the plasma membrane [12,45,46], however the
Figure 3. Sub-cellular distribution of ERa and MS-KIF18A in cells fractionated to cytoplasm (C) and nuclear/membrane (N/M)
compartments. Whole lysates (A) and IP (B) of fractionated cells were analyzed with anti-MS-KIF18A and anti-ERa. Results demonstrate a
representative experiment of four independent repeats.
doi:10.1371/journal.pone.0006407.g003
Figure 4. Interaction between NF-kB and MS-KIF18A or ERa. IP
with anti-p50 (1) with anti-p65 (2) WB performed with anti-MS-KIF18A
(A) with anti-ERa (B). Results revealed an association between MS-
KIF18A and p50, but not with p65 while ERa interacts with both forms
of NF-kB; p65 and p50. Results demonstrate a representative
experiment of three independent repeats.
doi:10.1371/journal.pone.0006407.g004
Figure 5. MS-KIF18A mRNA expression in vivo. Total RNA from bone marrow cells were harvested from mice (A) and rats (B, C) and analyzed
by qRT-PCR. (A) mRNA expression in bone marrow cells derived from young 4 month (white bars) and old 12 month (black bars) male mice; (B)
Young 3 month (white bars) and 14 month old (black bars) male and OVX female rats; (C) Sham, OVX and OVX+E2 female rats. MS-KIF18A mRNA
expression was normalized to G3PDH expression levels. Results are presented as mean values +/2 SD obtained from triplicates for each data point.
doi:10.1371/journal.pone.0006407.g005
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between ERa mobility and a putative cytoskeleton protein was
suggested, but no candidate protein has been identified thus far
[43]. Herein, we have shown that fractionated cells analyzed by
WB localizes the ERa is mainly at the nucleus/membrane
compartments, while MS-KIF18A is prevalent in cytoplasm
[11]. The association between MS-KIF18A and ERa is higher
in the cytoplasm, confirming the kinesins’ action in this
compartment. We have also shown that the complex formed
between these proteins is stimulated by 17bE2.
ERa signaling involves activation of MAPKs such as p38 and
ERK1/2 [31], resulting with various cell response. pERK protein
was earlier detected in association with ERa and MS-KIF18A,
suggesting a role for the MS-KIF18A in non-genomic activation of
ERa through the MAPK pathway [12]. Herein, we elaborated on
the protein complex between MS-KIF18A and ERa revealing it
regulation by estrogen. It is recognized that ERa binds NF-kBi n
various cells affecting cellular process such as inhibition of
inflammatory or during cell apoptosis [35]. NF-kB transcription
factor dimerize the p65 and p50 subunits to hetero-complex [48].
We detected an association between both NF-kB subunits and
ERa, while MS-KIF18A binds only the p50 subunit.
Estrogen regulates numerous cellular functions including the
remodeling of the cytoskeleton proteins and their composition. The
cytoskeleton is a dynamic network of proteins that undergoes
restructuring during cell division, formation of cell-cell or cell-ECM
interactions and cell migration. Cytoskeleton plays a role in
controlling of cells shape and influences gene expression
[22,49,50]. We earlier reported that 17bE2 affects the composition
of cytoskeleton proteins, such as thropomyosin and tubulin and
reorganization of actin fibers in MBA-15 cells [22]. Estrogen
induces the remodeling of both the F-actin and the intermediate
filament [50]. It was shown also in vivo, in OVX-estrogen depleted
rats an up-regulation of tropomyosin 2b and tropomyosin 1a
expression by 17bE2 [51]. Earlier we have shown the association
between MS-KIF18A and cytoskeleton proteins tubulin and actin
[11]. The current study provides new insights on the impact of
estrogen on the complex formed between ERa and MS-KIF18A.
The expression of MS-KIF18A mRNA and its’ regulation by
estrogen was analyzed in vivo in rats and mice. We have noticed an
age difference in MS-KIF18A expression: mRNA was higher
expressed in young animals then in old ones. Such differences may
account for the decrease in estrogen levels with aging [17,52,53]
suggesting a hormonal role in regulation of MS-KIF18A expression
in vivo. This observation was strengthened using OVX-estrogen
depleted rats which measured a decline in MS-KIF18A message as
compared to sham rats. When the OVX-rats were treated with
17bE2 we have shown the restoration of MS-KIF18A mRNA levels.
To unravel the mechanism of estrogen effects on MS-KIF18A
expression we analyzed the kinesin promoter activity by luciferase
reporter gene and ChIP assays. It is known that ERa activates
promoters when binds directly to palindrome ERE or half-site ERE
[39,54,55] or indirectly via accessory proteins (such as Fos and Jun)
at AP-1 binding sites or to GC-rich sequences via complex with Sp1
[40,56]. ERa also stimulates gene expression via interaction with
nuclear receptor NF-kB and this complex binding to promoters of
Figure 6. Luciferase measurements of MS-KIF18A promoter activity. (A) Schematic illustration of MS-KIF18A promoter-luciferase reporter
constructs. MCF-7 cells transfection with MS-KIF18A promoter cloned in luciferase reporter plasmid (pGLuc-K) or promoter less pGL3-basic along with
b-galactosidase vector. (B) Cells treated (black bars) or not (white bars) with 17bE2 (10
28 M) for 24 h; (C) 17bE2 (10
28 M) or/and ICI-182,780 (10
27 M)
were added to the cultures for 1 h (white bars) or 24 h (gray bars). Promoter activities are expressed as luciferase values normalized for b-
galactosidase levels. A value of 100% was given to the basal promoter activity elicited by the pGLuc-K construct in the absence of any treatment.
Results are mean6SD of 3 independent experiments, performed in duplicates.
doi:10.1371/journal.pone.0006407.g006
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KIF18A that contains non-palindromic half-site ERE, AP-1 and
NF-kB binding sites. The MS-KIF18A promoter was cloned under
luciferase reporter and transfected to MCF-7 cells. When these cells
were treated with either 17bE2 or ICI-182,780 we have noted a
similar inducible effect of the promoter activity while the combined
17bE2/ICI-182,780 treatment had an additive effect. MS-KIF18A
mRNAlevelswere quantifiedby qPCR and have shown anincrease
in cells treated with either 17bE2 or ICI-182,780. The rational for
the ICI-182,780 effect shown here lies in the fact that this drug is no
more considered as an estrogen antagonist and reports present a
role for its agonistic action. The agonist property of ICI-182,780
was observed in vivo on bonegrowth [57]. Cells derived from human
breast tumor tissues were analyzed on HTS affymetrix gene chip
resulted with an up-regulation of gene expression when treated by
estrogen and even more by ICI-182,780 [58]. Modulation by ICI-
182,780 resulted with up regulation of quinine reductase in MCF-7
cells [59], ERRa in SKBR3 cells [60] and spinophilin in
hippocampus neurons [61]. The promoter activation by ICI-
182,780 is proposed to act via ER binding on AP-1 sites, but not via
ERE [62]. Moreover, the ERa-ICI-182,780 complexes that
sequester transcriptional repressors away from AP-1 sites allow an
unrestricted transcription [63,64]. From the current study the
indication is that binding of 17bE2 and ICI-182,780 to ERa
increases the receptor binding to MS-KIF18A promoter and allows
its activation, leading to an increase in message transcription. Using
the ChIP analysis we have shown that ERa and pcJun bind to MS-
KIF18A promoter in MCF-7 and MBA-15 cells that are regulated
by 17bE2 and by ICI-182,780. In another study, we have shown
that ERa and cJun are differentially regulated when bind to SVEP1
promoter. In cells treated by 17bE2 it was shown an increase of the
TF binding but not when treated by ICI-182,780 [65].
Complementarywith reporter gene and ChIP assayswe analyzed
the role of estrogen on MS-KIF18A mRNA and protein expression.
It was noted that MS-KIF18A mRNA expression increased after
cells were challenged with 17bE2 or ICI-182,780. Furthermore,
inhibition of transcription with ActD and 17bE2 stabilized MS-
KIF18A mRNA and decreased its’ degradation. MS-KIF18A
protein levels also increased following 17bE2 treatment. Metabolic
labeling assay confirmed that 17bE2 accelerates MS-KIF18A
turnover. Taken together, the results elaborated on the effect of
estrogen on MS-KIF18A expression, lifetime and degradation.
In summary, we have shown the interaction between MS-KIF18A
and ERa as its cargo in in vitro and in vivo assays using different
biochemical and molecular approaches. Moreover, the involvement of
k i n e s i ni nE R a signaling was demonstrated. Furthermore, we have
shown for the first time regulation of MS-KIF18A mRNA expression
and protein turnover by estrogen, implying the kinesins’ function in
estrogen-dependent manner. These results can lead to further
investigation of metabolic regulation in the mesenchymal stem cells
that play a role in estrogen regulated maintenance of bone in
metabolic diseases or in cancer.
Materials and Methods
Animals and Experimental Design
ICR mice age 4-month (young) and 12-month (old) old (n=10 in
each group). Fischer 344 male and female rats age 90-day (young)
and 11-month (old) old (n=13–18 rats in each group from both sex).
Female rats were subdivided into a control sham group (abdominal
Figure 7. Chip assay of ERa and AP-1 binding to MS-KIF18A promoter. A-C Bar histogram of qPCR analysis of amplified MS-KIF18A promoter
in MCF-7 ChIPed by anti-ERa (A) or by anti-pcJun (B), and in MBA-15 cells were ChIPed by anti-ERa (C). All the results presented as mean values +/2
SD obtained from three different experiments each performed in triplicates for each data point.
doi:10.1371/journal.pone.0006407.g007
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implanted with 90-day slow-release pellets of 17b-E2 [17]. Animals
were maintained and treated according to the Institutional Animal
Care and Use Committee at the Tel Aviv University.
Cell culture
We used two cell lines known for their response to estrogen:
MBA-15, a pre-osteogenic stromal cell line [22] and MCF-7 breast
carcinoma cell line. Both were cultured in growth medium;
Dulbecco’s Modified Essential Medium (DMEM) (Gibco, USA)
with the addition of 10% heat-inactivated fetal calf serum (FCS)
(Biological Industries, Israel), supplemented with 1% glutamine
and 1% penicillin/streptomycin in a humidified atmosphere of 5%
CO2 at 37uC. Before cells’ were treatment with 10
28 M1 7 bE2 or
10
27 M ICI-182,780, they were incubated in 3% serum stripped
medium for 48 h. Where specified, cells were treated with 5 mg/
ml actinomycin D (Sigma, USA) a transcription inhibitor.
Bioinformatics analysis
60 kb of genomic sequence at 59-flanking upstream the
transcription start site (TSS) of MS-KIF18A gene was analyzed
to identify the gene-putative promoter. The analysis applied
Promoter 2.0 Prediction Server (http://www.cbs.dtu.dk/services/
Promoter) for promoter definition and MatInspector software
(http://www.genomatix.de) for transcription factor binding sites
identification. All primers were constricted using Primer3 Software
(http://frodo.wi.mit.edu/cgi-bin/primer3).
Putative MS-KIF18A promoter cloning and activity
1.5-kb 59-flanking upstream the transcription start site (TSS)
promoter sequence segment was amplified from genomic DNA
using the 59 TACCAAGACCAGCAGCACAC and 39 TAAG-
GAGATCCCTGCCCTTC primers. The PCR fragment was
verified by sequencing then restricted by Bgl II and Bcl I and a
1.3-kb segment was cloned upstream of a luciferase reporter gene
into pGLuc-basic vector (New England BioLabs, USA). The MS-
KIF18A promoter reporter plasmids named pGLuc-K.
MCF-7 cells seeded in 6-well plates, after 48 h cells were
transfected with 1.3 mg of the pGLuc-K or promoterless pGL3-
basic along with 0.3 mgo fb-galactosidase expression plasmid
(pCMVb; Clontech, Palo Alto, CA), using the jetPEI
TM
transfection reagent (Polyplus Transfection, Illkirch, France). After
24 hrs media was changed to 3% serum stripped medium
supplemented with 10
28 M1 7 b-E2 and 10
27 M ICI-182,780
for 1 h or 24 h then medium was collected and cells were
harvested for luciferase activity (New England BioLabs, USA) and
b-galactosidase activity [66]. Promoter activities are expressed as
luciferase values normalized to b-galactosidase levels.
mRNA and gene expression analysis by real-time
quantitative PCR
Total RNA was extracted from cells (EZ RNA kit, Biological
Industries, Beit Haemek, Israel) and reverse transcribed to cDNA
using Reverse-iT 1
st Strand Synthesis Kit (ABgene House, AB-
0789) and oligo-dT primer (Takara Shuzo Co. Ltd., Seta, Japan).
The cDNA used as template for polymerase chain reaction (PCR),
using primers for MS-KIF18A from human, rat and mouse
(Table 1). Amplified PCR products were detected by SYBR Green
(ABgene House, USA). Verification of a single product amplified
was checked for each primer pair by analysis of product melt curves
on (MxPro
TM QPCR Software, Stratagene, USA). MS-KIF18A
cDNA PCR products were subjected to dissociation curve analysis
resulting with fluorescence peak corresponding to the MS-KIF18A
product centered at 80uC in rats and at 82uC in mice and humans.
Primer-dimmers were distinguishable at 76uC. Level of expression
for PCR products was normalized to G3PDH gene expression.
Experiments were performed with triplicates for each data point.
Chromatin immunoprecipitation (ChIP) analysis of
regulatory factor binding to putative MS-KIF18A
promoter in human and mouse cells [67]
For assay, DNA was extracted from input chromatin fractions
and complex was immunopercipitated with anti-ERa (Stressgen,
Figure 8. MS-KIF18A mRNA expression presented by bar
histogram of qPCR analysis from (A) MCF-7 cells treated or
untreated for 60 min with 10
28 M1 7 bE2 (E2)o r1 0
27 M ICI-
182,780 (ICI) (B) MBA-15 cells treated with 17bE2 for 2 h and
24 h. (C) Effect of Act D on the stability of MS-KIF18A mRNA in MBA-15
cells treated in presence of 17bE2 for 6 h. The MS-KIF18A mRNA is
samples were normalized to G3PDH for each data point. Results are
presented as mean values +/2 SD obtained from three different
experiments each performed in triplicates for each data point.
doi:10.1371/journal.pone.0006407.g008
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DNA served a template to amplify promoter of MS-KIF18A gene,
with specific primers (Table 2) using real-time quantitative PCR.
Input DNA was used as a positive control and for standard curve.
The fluorescence peak dissociation corresponding to PCR product
centered at 85uC and was distinguishable from the peak of primer-
dimmer centered around 79–80uC.
Immunological methods
Cells’ were collected for immunoprecipitation (IP) or whole lysate
(WL) analysis; SDS-PAGE gel and Western blot (WB). Cells were
washed twice with ice-cold PBS and collected in presence of
protease inhibitors (phenylmethylsulfonyl fluoride, PMSF, 1 mM;
1-chloro-3-tosylamido-4-phenyl-2-butanone, TPCK, 10 mg/ml;
aprotinin, 10 mg/ml and phosphatase inhibitors cocktails I and II
(Sigma, USA). Samples were spin down at 1500 rpm for 4 min,
lysed in lyses buffer consisting of 50 mM Tris pH 7.5, 150 mM
NaCl, 1% NP-40; protease and phosphatase inhibitors; incubated
for 20 min at 4uC and centrifuged at 16,0006g for 5 min. For WL
the samples were resuspended in Lamelli sample buffer and boiled
Figure 9. Estrogen effects on MS-KIF18A protein expression and turnover. (A) Lysates of MBA-15 cells challenged with 10
28 M1 7 bE2 for
1 h, 2 h, 4 h and 20 h were analyzed by WB with anti-MS-KIF18A and compared to the untreated control at 1 h (C 1 h) and 20 h (C 20 h). (B) MBA-15
cells were pretreated with 10
28 M1 7 bE2 for duration of 6 h, 24 h or 48 h, metabolic labeled with Met/Cis-S
35, chased for various time periods from
1 h to 36 h, lysed, IPed with anti-MS-KIF18A and loaded on SDS-PAGE gel. (C) A 100 kDa protein confirmed as MS-KIF18A by IP and WB with anti-MS-
KIF18A. Results are of representative experiment of a series repeated three times.
doi:10.1371/journal.pone.0006407.g009
Table 1. Primers used for mRNA expression analyzed by PCR.
Gene Sequence
MS-KIF18A Mouse cDNA sense 59 TCAATCAAAATGTCCGTAT 39
antisense 59 GGCTTTCTGTTCTTCATAGG 39
MS-KIF18A Human cDNA sense 59 GTGCCATCCTACATGGCAATG 39
antisense 59 TGTCGAACACGTTTGGCAAA 39
MS-KIF18A Rat cDNA sense 59 CAAAATGGTGATATTCCCGAGG 39
antisense 59 CAGCCAGAGTCATCATGTGTCC 39
G3PDH sense 59 ACCACAGTCCATGCCATCAC 39
antisense 59 TCCACCACCCTGTTGCTGTA 39
doi:10.1371/journal.pone.0006407.t001
Table 2. Primers used for ChIP analysis.
Gene Sequence
MS-KIF18A Mouse promoter sense 59 TTTTACAGGCCCGCAGACTC 39
antisense 59 GAAGCAGCCACCTGGGATATT 39
MS-KIF18A Human promoter sense 59 ACGTGATGACATCACGCGAG 39
antisense 59 CTTTAATGTCCGCCTCCCAG 39
doi:10.1371/journal.pone.0006407.t002
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Protein-A sepharose beads (RepliGen, USA) were added to lysates
and samples were incubated overnight at 4uC. Immunocomplexes
wereprecipitated at 16,0006g for1 minand washedfourtimes with
lyses buffer. The washed beads were resuspended in Lamelli sample
buffer and boiled for 3 min. The proteins were separated on 8%
SDS-PAGE for 2 h 30 min and transferred to nitrocellulose for 1 h
30 min. For Western blot, the membranes were blocked with 5%
BSA in TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-
20, Sigma, USA) for 1 h at RT or overnight at 4uC and then
incubated with primary antibody. The membranes were washed
with TBST and incubated with goat anti-rabbit or goat anti-mouse
conjugated to biotin (Dako, Denmark) for 40 min at RT and with
extravidin-peroxidase for 30 min at RT (Sigma, USA) for detection
with chemiluminescent substrate (Pierce, USA).
Antibodies
Polyclonal anti-MS-KIF18A (1:1300) [10,12]; monoclonal anti-
MS-KIF18A (1:500) [11]; anti-ERa (1:800) (SRA-1010, Stressgen,
Canada), anti-p65 and anti-p50 (Santa Cruz, USA).
Metabolic Labeling and Immunoprecipitation
MBA-15 cells were grown to 70% confluence in 100 mm dishes,
cells were pretreated with 10
28 M1 7 bE2 for 6 h, 24 h and 48 h.
The medium was replaced with medium depleted of serum for 1 h
and cells were metabolically labeled in the presence or absence of
17bE2 for 1 h at 37uC using Redivue promix S
35 label (200 mCi/
sample; Amersham) in methionine and cysteine-free Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 3%
stripped FCS. At the end of each time point, cells were washed
twice with PBS and with DMEM supplemented with 3% stripped
FCS with or without 17bE2 for variable periods of time. Cells were
lysed in 50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40 and
protease and phosphatase inhibitors and MS-KIF18A was
immunoprecipitated overnight at 4uC using anti-MS-KIF18A
antibody and protein A sepharose beads (RepliGen, USA). The
immunocomplex was washed three time with lysis buffer, resolved
in 8% SDS-PAGE, and detected using Kodak BioMax MS Film.
Cell fractionation
Cells (1610
7) were washed twice with 3 ml of cold PBS,
resuspended in 100 ml Buffer A (10 mM HEPES, pH 7.4, 10 mM
KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.025% NP-40) with
protease inhibitors (1 mg/ml aprotinin, 1 mg/ml TPCK, 1 mg/
ml pepstatin A, 0.2 mM PMSF) and incubated on ice for 20 min
followed with centrifugation at 7500 rpm for 10 min at 4uC and
the cytoplasm extract was removed, frozen and stored at 280uC.
The pellet was resuspended in 50 ml Buffer B (20 mM HEPES,
pH 7.4, 420 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM
EDTA, 25% Glycerol) with protease inhibitors. The nuclear
suspension was stirred vigorously on ice for 30 min. The sample
was centrifuged at 15 000 rpm for 12 min at 4uC, and the
nuclear/membrane extract was frozen and stored at 280uC. The
protein concentration of cytoplasm and nuclear/membrane
extracts was determined by the NanoDrop (ND-1000 Spectro-
photometer, NanoDrop Technologies, Inc., USA).
Binding assay for recombinant proteins
MS-KIF18A recombinant proteins were expressed at the
Structural Proteomics Center, Weizmann Institute of Science, Israel.
Recombinant ERa was purchased (Sigma, USA). For experiments
we used 0.25 mg of protein and pull down was performed in presence
of either poly or monoclonal anti-MS-KIF18A, anti-ERa with 25 ml
Protein-A sepharose beads (RepliGen, USA) overnight at 4uC. Then
beads were spanned down, re-suspended with loading buffer and
protein complex was analyzed by western blot.
Statistical analysis
Statistical analyses were carried out by Student’s t-test, where
values of p,0.05 are statistically significant. * is p-value#0.05, **
is p-value#0.01, *** is p-value#0.001.
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